Effect of selective phosphodiesterase 3 inhibition on the early and late asthmatic responses to inhaled allergen

British Journal of Clinical Pharmacology

Volumn 45, Issue 4, 1998, Pages 387-391

  Bardin, Philip G ^b   Dorward, Martina A ^a   Lampe, Fiona C ^a   Franke, Brigitte ^c   Holgate, Stephen T ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c Sandoz Pharma Ltd   (Switzerland)

Author keywords

Allergen; Asthma; Phosphodiesterase inhibitors

Indexed keywords

8 [[1 (3,4 DIMETHOXYPHENYL) 2 HYDROXYETHYL]AMINO] 3,7 DIHYDRO 7 (2 METHOXYETHYL) 1,3 DIMETHYL 1H PURINE 2,6 DIONE; 8 AMINO 3,7 DIHYDRO 7 (2 METHOXYETHYL) 1,3 DIMETHYL 1H PURINE 2,6 DIONE; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTHMA; BRONCHODILATATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG PROTEIN BINDING; DRUG SPECIFICITY; ENZYME INHIBITION; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MALE; MEDICAL NEBULIZER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADOLESCENT; ADULT; ALLERGENS; ASTHMA; BRONCHODILATOR AGENTS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INHALATION EXPOSURE; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PLACEBOS; PURINONES;

EID: 0031885147     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00689.x     Document Type: Article

References (11)

1. Rabe TJ, Magnussen H, Dent G. Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. Eur Respir J 1995; 8: 637-642.
2. Raeburn D, Souness JE, Tomkinson A, Karlsson J-A. Isozyme selective cyclic nucleotide phosphodiesterase inhibitors: Biochemistry, pharmacology and therapeutic potential in asthma. Prog Drug Res 1993; 40: 9-32.
3. Turner CR, Andersen CJ, Smith WB, Watson JW. Effects of rolipram on responses to acute and chronic antigen exposure in monkeys. Am J Respir Crit Care Med 1994; 149: 1153-1159.
4. Morley J, Chapman ID, Mazzoni L. SDZ MKS492. Agents Actions 1991; 34: 403-410.
5. Giembycz MA, Dent G. Prospects for selective cyclic mucleotide phosphodiesterase inhibitors in the treatment of bronchial asthma. Clin Exp Allergy 1992; 22: 337-344.
6. Israel E, Mathur PN, Tashkin D, Drazen JM. LY 186655 prevents bronchospasm in asthma of moderate severity. Chest 1988; 91: 715-718.
7. Brunnée T, Engelstätter R, Steinijans VW, Kunkel G. Bronchodilatory effect of inhaled zardaverine, a phosphodiesterase III and IV inhibitor, in patients with asthma. Eur Resp J 1992; 5: 982-985.
8. Rudd RM, Gellert AR, Studdy PR, Geddes DM. Inhibition of exercise-induced asthma by an orally absorbed mast cell stabiliser. Br J Dis Chest 1983; 77: 78-86.
9. Reiser J, Yeang Y, Warner JO. The effect of zaprimast, an orally absorbed mast cell stabiliser on exercise - induced asthma in children. J Dis Chest 1986; 80: 157-163.
10. Giembycz MA. Could isoenzyme-selective phosphodiesterase inhibitors render bronchodilator therapy redundant in the treatment of bronchial asthma? Biochem Pharmacol 1992; 43: 2041-2051.
11. Fujimura M, Kamio Y, Saito M, Hashimoto T, Matsuda T. Bronchodilator and bronchoprotective effects of cilostazol in humans in viva. Am J Respir Crit Care Med 1995; 151: 222-225.